Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

1

Revenue 2017

Pfizer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Pfizer's sales performance.

Pfizer

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions. The first drug to treat disease progression in patients with an advanced form of multiple sclerosis was among five new ... Also receiving a recommendation for restriction is

BMS, Celgene merger should close this week after FTC okay

BMS, Celgene merger should close this week after FTC okay The deal will create a combined company with annual revenues in excess of $34bn, making it the sector’s fourth biggest firm behind Pfizer, Novartis and Roche.

Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

Amarin wins FDA advisory nod for Vascepa cardiovascular expansion These gains also lend more credit to the ongoing  speculation that Pfizer, among other companies, is interested in a possible buyout of Amarin.

Strengthening business competition and reducing anti-competitive practices

Strengthening business competition and reducing anti-competitive practices One of the largest was the £84.2m fine against Pfizer in 2016 for its 2, 600% price increase on an anti-epilepsy drug supplied to the NHS.

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor A number of other major pharma companies such as Pfizer, Allergan, Merck &Co and Bristol-Myers Squibb are pursuing treatments in NASH, making the race to market a close one.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics